50.61
price up icon0.16%   0.08
pre-market  Pre-market:  51.02   0.41   +0.81%
loading
Sanofi Adr stock is traded at $50.61, with a volume of 1.49M. It is up +0.16% in the last 24 hours and up +5.59% over the past month. Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
See More
Previous Close:
$50.53
Open:
$50.61
24h Volume:
1.49M
Relative Volume:
0.66
Market Cap:
$124.24B
Revenue:
$43.23B
Net Income/Loss:
$6.79B
P/E Ratio:
12.60
EPS:
4.0174
Net Cash Flow:
$9.17B
1W Performance:
+3.20%
1M Performance:
+5.59%
6M Performance:
-7.07%
1Y Performance:
-8.35%
1-Day Range:
Value
$50.53
$51.00
1-Week Range:
Value
$49.48
$51.23
52-Week Range:
Value
$44.73
$60.12

Sanofi Adr Stock (SNY) Company Profile

Name
Name
Sanofi Adr
Name
Phone
-
Name
Address
-
Name
Employee
82,878
Name
Twitter
@sanofi
Name
Next Earnings Date
2024-10-25
Name
Latest SEC Filings
Name
SNY's Discussions on Twitter

Compare SNY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
SNY
Sanofi Adr
50.61 121.56B 43.23B 6.79B 9.17B 4.0174
Drug Manufacturers - General icon
LLY
Lilly Eli Co
709.82 625.77B 53.26B 13.80B -50.20M 15.30
Drug Manufacturers - General icon
JNJ
Johnson Johnson
178.93 424.47B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
209.50 364.92B 58.33B 3.73B 18.24B 2.10
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
126.82 240.07B 53.40B 13.68B 16.89B 6.9231
Drug Manufacturers - General icon
MRK
Merck Co Inc
86.08 210.36B 63.43B 16.42B 14.72B 6.49

Sanofi Adr Stock (SNY) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-08-25 Upgrade JP Morgan Neutral → Overweight
Apr-15-25 Initiated Exane BNP Paribas Outperform
Mar-21-25 Initiated Goldman Neutral
Jan-30-25 Upgrade Deutsche Bank Sell → Hold
Jul-26-24 Reiterated Argus Buy
Jan-23-24 Initiated Morgan Stanley Equal-Weight
Jan-16-24 Resumed UBS Buy
Dec-05-23 Downgrade JP Morgan Overweight → Neutral
Oct-30-23 Downgrade Stifel Buy → Hold
Sep-06-23 Upgrade Berenberg Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Apr-28-23 Downgrade Deutsche Bank Hold → Sell
Mar-27-23 Upgrade Barclays Equal Weight → Overweight
Dec-13-22 Resumed Morgan Stanley Overweight
Aug-12-22 Upgrade Deutsche Bank Sell → Hold
Aug-09-22 Downgrade UBS Buy → Neutral
May-23-22 Initiated SVB Leerink Outperform
Sep-27-21 Upgrade SVB Leerink Mkt Perform → Outperform
Jan-15-21 Initiated Deutsche Bank Sell
Sep-29-20 Initiated Berenberg Hold
Mar-17-20 Upgrade Barclays Underweight → Equal Weight
Mar-11-20 Upgrade Goldman Neutral → Buy
Feb-11-20 Initiated SVB Leerink Mkt Perform
Jan-06-20 Upgrade JP Morgan Neutral → Overweight
Sep-23-19 Upgrade Guggenheim Neutral → Buy
Sep-20-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-03-19 Initiated Bernstein Outperform
Aug-14-19 Upgrade UBS Neutral → Buy
Dec-11-18 Upgrade Jefferies Hold → Buy
Nov-01-18 Upgrade Barclays Underweight → Equal Weight
Oct-09-18 Initiated Guggenheim Neutral
Sep-10-18 Upgrade BofA/Merrill Neutral → Buy
Aug-10-18 Upgrade Citigroup Neutral → Buy
Mar-23-18 Upgrade Liberum Hold → Buy
Jan-23-18 Downgrade Barclays Equal Weight → Underweight
Dec-06-17 Downgrade BofA/Merrill Buy → Neutral
Dec-01-17 Downgrade Morgan Stanley Overweight → Underweight
Nov-15-17 Upgrade Barclays Underweight → Equal Weight
Aug-30-17 Upgrade HSBC Securities Reduce → Hold
View All

Sanofi Adr Stock (SNY) Latest News

pulisher
Aug 14, 2025

MacroGenics Revenue Doubles in Q2 - The Motley Fool

Aug 14, 2025
pulisher
Aug 05, 2025

Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar

Aug 05, 2025
pulisher
Aug 05, 2025

Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary - Seeking Alpha

Aug 05, 2025
pulisher
Jul 31, 2025

Sanofi ADR (SNY) Stock: A Year of Stock Market Ups and Downs - investchronicle.com

Jul 31, 2025
pulisher
Jul 31, 2025

Sanofi ADR earnings beat by $0.63, revenue fell short of estimates - Investing.com Nigeria

Jul 31, 2025
pulisher
Jul 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - cnhinews.com

Jul 27, 2025
pulisher
Jul 24, 2025

Sanofi: Reassessing Our Moat Rating for This Leader in Immunology, Vaccines, and Rare Diseases - Morningstar

Jul 24, 2025
pulisher
Jul 22, 2025

BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study - Ariva

Jul 22, 2025
pulisher
Jul 21, 2025

AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com

Jul 21, 2025
pulisher
Jul 14, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SanofiSNY - FinancialContent

Jul 14, 2025
pulisher
Jul 01, 2025

Adagene stock gains as Sanofi expands agreement (ADAG:NASDAQ) - Seeking Alpha

Jul 01, 2025
pulisher
Jun 13, 2025

SNY’s 2023 Market Dance: Up 3.92% – Time to Invest? - investchronicle.com

Jun 13, 2025
pulisher
Jun 09, 2025

Sanofi: Information concerning the total number of voting rights and shares - GlobeNewswire Inc.

Jun 09, 2025
pulisher
Jun 02, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Jun 02, 2025
pulisher
Jun 02, 2025

France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion - The Globe and Mail

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi doubles down on immunology with $9.1bn Blueprint deal - Proactive financial news

Jun 02, 2025
pulisher
May 31, 2025

European ADR Index Slips As Pharma Stocks Buck The Trend - Finimize

May 31, 2025
pulisher
May 30, 2025

Regeneron and Sanofi: Disappointing Top-Line Results for Itepekimab From Two Phase 3 Trials - Morningstar

May 30, 2025
pulisher
May 30, 2025

Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure - Investor's Business Daily

May 30, 2025
pulisher
May 30, 2025

Market movers: Canopy Growth, Zscaler, Regeneron... - Proactive financial news

May 30, 2025
pulisher
May 30, 2025

Regeneron shares plunge after mixed COPD drug trial results - Proactive financial news

May 30, 2025
pulisher
May 29, 2025

Penicillin Market Research Report 2025 - GlobeNewswire Inc.

May 29, 2025
pulisher
May 29, 2025

Sanofi: New Anthem from Girl Band Raises Awareness of Type 1 Diabetes After Research Highlights Silent Struggle - Ariva

May 29, 2025

Sanofi Adr Stock (SNY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$116.14
price down icon 2.18%
drug_manufacturers_general PFE
$25.74
price up icon 1.42%
$295.76
price down icon 0.23%
drug_manufacturers_general NVO
$55.45
price up icon 2.12%
drug_manufacturers_general MRK
$86.08
price up icon 1.68%
Cap:     |  Volume (24h):